| ID Source | ID |
|---|---|
| PubMed CID | 11954226 |
| CHEBI ID | 31516 |
| MeSH ID | M0223567 |
| Synonym |
|---|
| doramectin (jan/usan/inn) |
| D01129 |
| 117704-25-3 |
| doramectin , |
| CHEBI:31516 |
| (1'r,2r,3s,4's,6s,8'r,10'e,12's,13's,14'e,16'e,20'r,21'r,24's)-2-cyclohexyl-21',24'-dihydroxy-12'-[(2r,4s,5s,6s)-5-[(2s,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-3,11',13',22'-tetramethylspiro[2,3-dihydropyran-6,6'-3 |
Doramectin (DRM) is a broad-spectrum antiparasitic drug used in veterinary medicine. It has been shown that DRM has anti-cancer effects.
Doramectin reduced pretreatment FEC by 99.1% in the first study. The drug was 100% effective in prevention of C. Nematode.
Six are the most effective and safe treatments for generalised canine demodicosis. To evaluate the toxic effects of ivermectin, doramectin and eprinomectin on the bloodfeeding behaviour of Triatoma infestans using a rodent model.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Abamectin was more toxic than doramectin." | ( Toxicity of abamectin and doramectin to soil invertebrates. Hogerwerf, L; Kolar, L; Kozuh Erzen, N; van Gestel, CA, 2008) | 0.93 |
| " This model can be used to identify toxic P-gp substrates with altered safety in dog populations and may reduce dog use in safety studies that are part of the drug approval process." | ( P-gp substrate-induced neurotoxicity in an Abcb1a knock-in/Abcb1b knock-out mouse model with a mutated canine ABCB1 targeted insertion. Buckely, LE; Jhingory, MV; Jones, YL; Lancaster, VA; Myers, MJ; Orzechowski, KL; Robl, MG; Swaim, HL; Swain, MD; Tinaza, CA; Yancy, HF, 2013) | 0.39 |
| " It was found that OXT and FLO have a stronger adverse effect on duckweed (EC50=3." | ( Aquatic toxicity of four veterinary drugs commonly applied in fish farming and animal husbandry. Białk-Bielińska, A; Kołodziejska, M; Kumirska, J; Maszkowska, J; Stepnowski, P; Steudte, S; Stolte, S, 2013) | 0.39 |
| "To evaluate the toxic effects of ivermectin, doramectin and eprinomectin on the bloodfeeding behaviour of Triatoma infestans using a rodent model." | ( Evaluation of the toxic effects of doramectin, ivermectin and eprinomectin against Triatoma infestans using a rat model. Dadé, M; Daniele, M; Mestorino, N, 2017) | 0.99 |
| " Our objective was to systematically review the literature to determine the most effective and safe topical or systemic therapy for canine generalised demodicosis." | ( Critically appraised topic for the most effective and safe treatment for canine generalised demodicosis. Foppa, C; Perego, R; Proverbio, D; Spada, E, 2019) | 0.51 |
| "The analysis of the best available evidence on March 5, 2018, suggests that six are the most effective and safe treatments for generalised canine demodicosis including (in alphabetical order): doramectin (oral or parenteral); fluralaner (oral); imidacloprid/moxidectin (topical); ivermectin (oral, not as first choice treatment); milbemycin oxime (oral); and sarolaner (oral)." | ( Critically appraised topic for the most effective and safe treatment for canine generalised demodicosis. Foppa, C; Perego, R; Proverbio, D; Spada, E, 2019) | 0.7 |
The pharmacokinetic behaviour of doramectin after a single subcutaneous administration and moxidectin following a single oral drench were studied in goats. The disposition of other avermectin-type endectocide compounds, dorAmectin (DRM) and abamectIn (ABM), was also assessed in the same Pharmacokinetic trial.
| Excerpt | Reference | Relevance |
|---|---|---|
| " This was explained by a lower clearance, a lower volume of distribution and, probably, a higher bioavailability of doramectin over ivermectin." | ( Comparative pharmacokinetics of doramectin and ivermectin in cattle. McKenzie, ME; Terhune, TN; Toutain, PL; Upson, DW, 1997) | 0.79 |
| " The apparent absorption rate of moxidectin was not significantly different after oral and subcutaneous administration but the extent of absorption, reflected in the peak concentration (C(max)) and the area under the concentration-time curve (AUC), of the subcutaneous injection (24." | ( Pharmacokinetics of moxidectin and doramectin in goats. Alvinerie, M; Carceles, CM; Diaz, MS; Escudero, E; Galtier, P; Sutra, JF, 1999) | 0.58 |
| " Oral bioavailability after drug ingestion due to allo-licking was 13." | ( Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin. Alvinerie, M; Bousquet-Mélou, A; Mercadier, S; Toutain, PL, 2004) | 0.55 |
| " The results of this study showed that the administration route affects plasma disposition kinetics, bioavailability and fecal elimination of DRM." | ( Plasma disposition and fecal elimination of doramectin after oral or intramuscular administration in horses. Alvinerie, M; Arboix, M; Godoy, C; Muñoz, L; Palma, C; Pérez, R, 2010) | 0.62 |
Injectable doramectin at a dosage of 200 micrograms/kg is safe and effective for treatment of gastrointestinal nematodiasis and louse infestations.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This approach led to the identification of formulations based upon sesame oil and ethyl oleate which gave more prolonged doramectin plasma concentrations with no loss in therapeutic efficacy and improved persistent efficacy following subcutaneous administration to cattle at a dosage of 200 micrograms kg-1." | ( Effect of formulation on the pharmacokinetics and efficacy of doramectin. Davison, E; Gibson, SP; Kaye, B; Lewis, D; Smith, DG; Weatherley, AJ; Wicks, SR, 1993) | 0.73 |
| " Treated animals received doramectin at a dosage of 200 micrograms kg-1, subcutaneously in the lateral midline of the neck." | ( Efficacy of doramectin against eyeworms (Thelazia spp.) in naturally and experimentally infected cattle. Kennedy, MJ; Phillips, FE, 1993) | 0.97 |
| "Plasma concentrations of doramectin in 40 cattle dosed by subcutaneous (sc) or intramuscular (i." | ( Pharmacokinetics and bioequivalence of parenterally administered doramectin in cattle. Hunter, RP; Jones, RM; Logan, NB; Lukaszewicz, J; Lynch, MJ; Mouzin, DE; Nowakowski, MA; Ryan, NI; Smith, DG, 1995) | 0.83 |
| "To evaluate the safety and efficacy of doramectin given by injection at a dosage of 200 micrograms/kg of body weight for treatment of gastrointestinal nematodiasis or louse infestations of cattle." | ( Field evaluation of doramectin for treatment of gastrointestinal nematode infections and louse infestations of cattle. Jones, RM; Logan, NB; Phillips, FE, 1996) | 0.89 |
| "Injectable doramectin at a dosage of 200 micrograms/kg is safe and effective for treatment of gastrointestinal nematodiasis and louse infestations of cattle under field conditions." | ( Field evaluation of doramectin for treatment of gastrointestinal nematode infections and louse infestations of cattle. Jones, RM; Logan, NB; Phillips, FE, 1996) | 1.01 |
| "Seven individual trials were conducted in Wyoming to evaluate the therapeutic efficacy of doramectin administered subcutaneously at a dosage of 200 micrograms kg-1 against multiple, natural infestations of cattle grubs or cattle lice." | ( Doramectin systemic activity against cattle grubs, Hypoderma lineatum and H. bovis (Diptera: Oestridae), and cattle lice, bovicola bovis (Mallophaga: Trichodectidae), Linognathus vituli and Solenopotes capillatus (Anoplura: Linognathidae), and Haematopinu Kumar, R; Lloyd, JE; Phillips, FE; Waggoner, JW, 1996) | 1.96 |
| "Doramectin, at a dosage of 200 micrograms/kg, is effective in controlling the prevalent gastrointestinal nematodes (adult and L4 stages) found in naturally infected calves." | ( Efficacy of doramectin for treatment of experimentally induced infection with gastrointestinal nematodes in calves. Couvillion, CE; Logan, NB; Pote, LM; Siefker, C, 1997) | 2.12 |
| "Endectocidal efficacy of doramectin administered intramuscularly at a dosage of 300 micrograms/kg was evaluated in 464 pigs naturally infected with intestinal nematodes or mange mites on 14 commercial farms in Japan." | ( Efficacy of doramectin against intestinal nematodes and sarcoptic manage mites in naturally infected swine. Fujii, T; Fukumoto, S; Kagota, K; Saeki, H; Takeda, S; Taneichi, A; Tsukaguchi, M, 1997) | 0.98 |
| "Plasma pharmacokinetics were compared for 40 cattle dosed by subcutaneous injection with doramectin or ivermectin (200 micrograms kg-1), commercial formulations of doramectin or ivermectin, 20 cattle per product)." | ( Comparative pharmacokinetics of doramectin and ivermectin in cattle. McKenzie, ME; Terhune, TN; Toutain, PL; Upson, DW, 1997) | 0.8 |
| " Calves in the D-group were treated with doramectin pour-on on days 0 and 56, at a dosage of 500 microg kg(-1) BW: calves in the C-group were designated as controls." | ( Field evaluation of a topical doramectin formulation for the chemoprophylaxis of parasitic bronchitis in calves. Claerebout, E; Dorny, P; Vercruysse, J; Weatherley, A, 1998) | 0.85 |
| "Seven studies were conducted under field conditions in North America to evaluate the therapeutic efficacy of doramectin in a pour-on formulation at a dosage of 500 microg/kg (1 ml/10 kg) for cattle harboring naturally-acquired infections of gastrointestinal nematodes, including species of Haemonchus, Ostertagia, Trichostrongylus, Bunostomum, Cooperia, and Oesophagostomum." | ( Field efficacy of doramectin pour-on against naturally-acquired, gastrointestinal nematodes of cattle in North America. Conder, GA; Illyes, EF; Keller, DS; Logan, NB; Meinert, TR; Rooney, KA, 1998) | 0.85 |
| " IVR and DOR are confirmed at 20 ppb levels in fortified salmon muscle; IVR is also confirmed in tissue from salmon dosed with the drug." | ( Confirmation of avermectin residues in food matrices with negative-ion atmospheric pressure chemical ionization liquid chromatography/mass spectrometry. Gonzales, SA; Hurlbut, JA; Pfenning, AP; Roybal, JE; Rupp, HS; Turnipseed, SB, 1999) | 0.3 |
| "Persistent anthelmintic efficacy of topical formulations (all at a dosage of 500 microg/kg) of doramectin (DOR), ivermectin (IVM), eprinomectin (EPR) and moxidectin (MOX), in comparison with untreated control cattle (CONT), was observed in stocker beef calves during a 112-day winter-spring grazing trial." | ( A comparison of persistent anthelmintic efficacy of topical formulations of doramectin, ivermectin, eprinomectin and moxidectin against naturally acquired nematode infections of beef calves. Clymer, BC; DeRosa, A; Guerino, F; Gurie, J; Loyacano, AF; Williams, JC, 1999) | 0.75 |
| " From Day 1 to 19 they were dosed orally with 2000 infective larvae of Dictyocaulus viviparus." | ( Induction of protective immunity to Dictyocaulus viviparus in calves while under treatment with endectocides. Canavan, A; Edgar, HW; Kenny, J; Mallon, TR; Taylor, SM, 2000) | 0.31 |
| ") at a dosage of 150 microg/kg." | ( The behaviour of doramectin in the gastrointestinal tract, its secretion in bile and pharmacokinetic disposition in the peripheral circulation after oral and intravenous administration to sheep. Gottschall, D; Hennessy, DR; Page, SW, 2000) | 0.65 |
| " All 7 dogs were treated with doramectin at a dosage of 200 microg/kg SC at 14-day intervals for 3 treatments." | ( Spirocerca lupi esophageal granulomas in 7 dogs: resolution after treatment with doramectin. Berry, WL, ) | 0.65 |
| " Precautions must be taken to ensure adequate dosing of every pig, and to avoid reinfestation due to poor biosecurity." | ( Elimination of mange mites Sarcoptes scabiei var. suis from two naturally infested Danish sow herds using a single injection regime with doramectin. Arnason, T; Cracknell, V; Jensen, JC; Nielsen, LH, 2002) | 0.52 |
| "2 mg/kg, the dosage registered for other host species." | ( Anthelmintic treatment in horses: the extra-label use of products and the danger of under-dosing. Matthee, S, 2003) | 0.32 |
| " Daily oral treatment with eprinomectin at a dosage of 200 microg/kg for 28 consecutive days produced a maximum concentration in the serum of 41." | ( Efficacy of eprinomectin and doramectin against Amblyomma americanum (Acari: Ixodidae) on cattle. Lohmeyer, KH; Miller, JA; Oehler, DD; Pound, JM, 2009) | 0.64 |
| " All subgroups received a subcutaneous injection at a dosage of 400 microg/kg body weight every 80 h on three occasions." | ( Comparison of efficacy of ivermectin and doramectin against mange mite (Sarcoptes scabiei) in naturally infested rabbits in Turkey. Güneli, E; Inceboz, T; Kaya, D; Kolatan, E; Yilmaz, O, ) | 0.4 |
| "Analysis of doramectin concentration in blood serum of pastured cattle injected repeatedly (12 treatments) at two different dosage rates and 28-day intervals throughout the year was used to predict the probability that cattle fever ticks could successfully feed to repletion during the interval between any two consecutive treatments." | ( Analysis of doramectin in the serum of repeatedly treated pastured cattle used to predict the probability of cattle fever ticks (Acari: Ixodidae) feeding to repletion. Davey, RB; Freeman, JM; Klavons, JA; Lohmeyer, KH; Olafson, PU; Pound, JM, 2012) | 1.14 |
| " The doramectin dosage of the deceased kitten was 380 μg/kg." | ( [Doramectin intoxication in 3 kittens]. Burgener, IA; Nentwig, A; Oevermann, A, 2014) | 1.83 |
| " The animals were allocated to two experimental groups of ten animals each: treated group - dosed with doramectin 200 μg/kg live weight (LW), and control group - dosed with saline solution 1 mL/50 kg LW." | ( First report of Dermatobia hominis resistant to doramectin in cattle. Borges, DGL; Borges, FA; Conde, MH; da Silva, MC; Freitas, MG, 2021) | 1.09 |
| Class | Description |
|---|---|
| macrolide | A macrocyclic lactone with a ring of twelve or more members derived from a polyketide. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 94 (33.10) | 18.2507 |
| 2000's | 116 (40.85) | 29.6817 |
| 2010's | 60 (21.13) | 24.3611 |
| 2020's | 14 (4.93) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (47.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 75 (24.83%) | 5.53% |
| Reviews | 5 (1.66%) | 6.00% |
| Case Studies | 12 (3.97%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 210 (69.54%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||